English
公司简介
|
核心技术
|
产品开发
|
最新研究成果
|
商务拓展
|
投资者
联系我们
核心技术与产品
最新研究成果
iAPA
TM
Technology
iVac-006 cancer vaccine
iVac-008 vaccine adjuvant
iVac-009 AIDS vaccine
Dendritic cell-based tumor vaccines…More>>
SOCS-1… antitumor immunity…More>>
New approaches to vaccine adjuvant…More>>
An alternative and effective HIV vaccine…More>>
Silencing of SOCS-1 enhances antigen presentation…More>>
Knocking the SOCS1 off DC…More>>
新闻动态
ImmunoVac, Inc. Announces Its Platform Technology for the Development of More Effective Tumor Vaccines as Published in Nature Medicine
ImmunoVac, Inc. announces an exclusive worldwide license agreement with Baylor College of Medicine for a novel immunotherapy technology
HIV Vaccine Takes Different Tack To Boost Immune Response
SOCS1 silencing could help enhance vaccines against HIV
SOCS1 silencing dramatically increases the anti-cancer efficacy of dendritic cell vaccines
快速导航
公司简介
核心技术
产品开发
最新研究成果
商务拓展
投资者
联系我们
新闻动态
New Data on Platform Technology Published in Nature Medicine
May, 2007 By Baylor College of Medicine
January, 2006 By Science Daily
January, 2006 By Medical Research News
February, 2005 By LeadDiscovery
更多...
友情连接
晨兴集团
贝勒大学医学院
网站建设
网站建设
网站建设
CopyRight ©
2007 ImmunoVac Inc All rights reserved.
Registrtion number：321321321
ImmunoVac, Inc. Announces Its Platform Technology for the Development of More Effective Tumor Vaccines as Published in Nature Medicine